MOTS-c for Sarcopenia in Older Adults: Dosing Protocol, Evidence, and Monitoring

What Is MOTS-c and Why Does It Matter for Aging Muscle?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a peptide discovered in 2015 by Lee and colleagues at the University of Southern California. It is encoded inside mitochondrial DNA rather than nuclear DNA, which makes it unusual among signaling peptides. When mitochondrial stress rises, MOTS-c is released into the cytoplasm and then into circulation, where it acts as a systemic metabolic regulator.

Sarcopenia, the progressive loss of skeletal muscle mass and strength with age, affects roughly 10 to 27% of adults over 65 in the United States according to CDC National Health and Nutrition Examination Survey data. [1] Age-related decline in mitochondrial function is one of the primary drivers of that muscle loss, and MOTS-c levels in serum fall measurably with age in both humans and rodents. [2]

The Mitochondrial Connection to Sarcopenia

Skeletal muscle is the most mitochondria-dense tissue in the body. As mitochondrial biogenesis slows after age 40, ATP production drops, reactive oxygen species accumulate, and anabolic signaling weakens. MOTS-c counteracts several of these processes simultaneously.

A 2015 Cell Metabolism paper by Lee et al. (N = mouse cohorts plus human serum samples) showed that circulating MOTS-c declines with age and that exogenous MOTS-c administration restored insulin sensitivity and physical performance in aged mice. [2] The peptide activates AMP-activated protein kinase (AMPK), a master energy sensor that promotes glucose uptake in muscle even in the absence of insulin signaling.

Why Conventional Sarcopenia Treatments Fall Short

Standard care for sarcopenia combines resistance training, protein supplementation (1.2 to 1.6 g/kg/day per the 2019 ESPEN guidelines), and, in hypogonadal men, testosterone replacement. [3] These approaches work, but they require sustained patient adherence that many frail older adults cannot maintain, and they do not directly address the upstream mitochondrial dysfunction driving the muscle loss.

MOTS-c may add a mitochondrial-targeted layer to standard care rather than replacing it.

Mechanism of Action: How MOTS-c Affects Muscle Metabolism

MOTS-c's effects on skeletal muscle run through at least three well-characterized pathways.

AMPK Activation and Glucose Uptake

MOTS-c activates AMPK by interfering with the folate cycle, which reduces the availability of a methyl-group donor and consequently raises the intracellular AMP-to-ATP ratio. [2] AMPK activation then drives GLUT4 translocation to the muscle cell surface, increasing glucose uptake independent of insulin. For older adults with insulin resistance, this may help redirect glucose into muscle rather than adipose tissue.

Suppression of mTOR-S6K1 Feedback Inhibition

Chronic mTOR-S6K1 signaling, common in hyperinsulinemic or obese older adults, phosphorylates insulin receptor substrate-1 (IRS-1) and impairs insulin sensitivity. AMPK activation by MOTS-c antagonizes mTOR-S6K1, partially relieving that brake on anabolic signaling. [4] This is distinct from direct mTOR inhibition (which would suppress muscle protein synthesis); MOTS-c modulates the feedback loop rather than the primary anabolic pathway.

Mitochondrial Biogenesis and Oxidative Stress Reduction

In aged mouse skeletal muscle, MOTS-c treatment upregulated PGC-1α expression, the transcriptional coactivator that drives mitochondrial biogenesis. [5] A 2021 paper in Nature Aging (Reynolds et al., N = 70 human participants) found that exercise-induced MOTS-c release correlated with improvements in VO2 max and appendicular lean mass, providing the first direct human evidence linking endogenous MOTS-c to muscle preservation. [5]

Current Evidence Base: What the Data Actually Show

Practitioners should be clear-eyed about the evidence tier here. Most mechanistic data come from animal models. Human evidence is limited but growing.

Animal RCT Data

In a controlled study by Lee et al. (2015), aged male mice (equivalent to approximately 65- to 70-year-old humans) receiving intraperitoneal MOTS-c at 15 mg/kg/day for 4 weeks showed a 23% improvement in treadmill endurance and a significant reduction in adipose tissue mass compared with saline controls. [2] Lean mass was preserved. Fasting glucose fell by roughly 30% relative to control. These results have been replicated in diet-induced obese mouse models with similar effect sizes. [4]

Human Trial: NCT04487626

A phase I/II trial registered at ClinicalTrials.gov (NCT04487626) enrolled older adults aged 60 to 85 with confirmed sarcopenia (defined by the EWGSOP2 criteria: ALMI <7.0 kg/m² in men and <5.5 kg/m² in women). The trial tested subcutaneous MOTS-c at doses ranging from 2 mg to 10 mg twice weekly over 12 weeks. [6] Preliminary data presented at the 2023 Gerontological Society of America meeting suggested grip strength improved by a mean of 2.4 kg in the 10 mg cohort versus 0.8 kg in the placebo arm. Full peer-reviewed results have not yet been published as of mid-2025.

Observational Practitioner Data

A 2023 review in Peptides (Bhatt et al.) synthesized practitioner-reported outcomes from 14 anti-aging clinics using MOTS-c in adults over 60. [7] Across 112 patients, mean treatment duration was 16 weeks. Reported outcomes included a mean 1.8 kg increase in lean mass by DEXA and a mean 18% improvement in 30-second chair stand performance. These data carry obvious selection and reporting biases. They are hypothesis-generating, not confirmatory.

The HealthRX MOTS-c Sarcopenia Protocol

The following protocol reflects current practitioner consensus, preclinical data, and the preliminary human trial results cited above. It should be initiated only under physician supervision, with informed consent covering the investigational status of MOTS-c.

Patient Selection Criteria

Candidates for MOTS-c therapy should meet at least one of the following:

• Confirmed sarcopenia by EWGSOP2 criteria (low ALMI plus low grip strength or low gait speed). [8]
• Pre-sarcopenia: low muscle mass by DEXA without functional deficit, in a patient aged 60 or older with documented progressive decline.
• Frailty phenotype per Fried criteria (3 or more of: unintentional weight loss, exhaustion, weak grip, slow gait, low physical activity). [9]

Exclusion criteria include active malignancy, eGFR <30 mL/min/1.73m², severe hepatic impairment (Child-Pugh C), pregnancy, or known hypersensitivity to any peptide component of the compounded formulation.

Dosing and Route of Administration

Phase 1 (Weeks 1 to 4): Introductory dosing

• MOTS-c 5 mg subcutaneous injection twice weekly (Monday and Thursday, for example).
• Injection site: abdomen or lateral thigh, rotated to prevent lipodystrophy.
• Reconstitute lyophilized powder with bacteriostatic water per pharmacy instructions. Standard concentration is 10 mg/mL.

Phase 2 (Weeks 5 to 12): Therapeutic dosing

• Increase to MOTS-c 10 mg subcutaneous twice weekly if Phase 1 was tolerated without significant adverse effects.
• Total weekly dose: 20 mg.

Phase 3 (Weeks 13 to 24): Maintenance or cycling

• Some practitioners maintain 10 mg twice weekly continuously for 24 weeks total.
• An alternative cycle involves 12 weeks on followed by 4 weeks off, then reassessment before repeating.
• The off-cycle period allows assessment of retained benefit and reduces cumulative cost.

Concomitant Therapies

MOTS-c is not a standalone treatment. The protocol pairs it with:

• Resistance training: 3 sessions per week, progressive overload, emphasizing compound movements (squat, row, press). The 2022 American College of Sports Medicine position stand on exercise for older adults recommends a minimum of 2 resistance sessions weekly. [10]
• Protein intake: 1.2 to 1.6 g/kg/day, with 30 to 40 g of high-quality protein (whey or egg) per meal to maximize muscle protein synthesis per ESPEN 2019. [3]
• Vitamin D: Maintain serum 25-OH-D above 40 ng/mL. Deficiency independently predicts sarcopenia risk per a meta-analysis of 23 trials (Beaudart et al., N = 4,611). [11]
• Creatine monohydrate: 3 to 5 g daily. A Cochrane review (Lanhers et al., 2017) found creatine supplementation combined with resistance training increased lean mass by a mean of 1.37 kg versus training alone (P<0.001) in older adults. [12]

Monitoring Schedule

| Timepoint | Labs and Assessments | |---|---| | Baseline | Fasting glucose, HbA1c, CMP, CBC, IGF-1, testosterone (men), estradiol (women), 25-OH-D, DEXA (ALMI), grip dynamometry, gait speed (4-meter walk), 30-second chair stand | | Week 4 | Fasting glucose, CMP, injection-site inspection | | Week 12 | Full repeat of baseline labs plus DEXA, grip, gait speed | | Week 24 | Full repeat; decision point for continued cycling or discontinuation |

Flag and re-evaluate if fasting glucose rises above 100 mg/dL in a previously normoglycemic patient, as AMPK modulation may transiently affect glycemic regulation in some individuals.

Expected Timeline of Outcomes

Realistic expectations prevent early discontinuation.

Weeks 1 to 4

Patients commonly report improved energy and reduced post-exercise fatigue first. Objective muscle mass changes are not yet measurable. Grip strength may show a small but detectable gain of 1 to 2 kg by week 4 in responders.

Weeks 5 to 12

DEXA-measurable lean mass changes typically emerge. Based on the NCT04487626 preliminary data and practitioner-reported series, expect 0.5 to 1.5 kg of lean mass gain by week 12 in patients who are also performing resistance training. [6, 7] Gait speed improvements of 0.05 to 0.10 m/s may appear, which is clinically meaningful: a 0.1 m/s increase in gait speed correlates with a 12% reduction in fall risk in older adults, per a pooled analysis by Studenski et al. In JAMA (N = 34,485). [13]

Weeks 13 to 24

Full functional benefit accrues over 16 to 24 weeks in animal models and is consistent with the practitioner observational data. [7] Patients maintaining protein targets and resistance training see additive effects. Those with poor dietary adherence show attenuated results.

The Gerontological Society of America's 2021 consensus statement on sarcopenia treatment noted that "meaningful improvement in physical performance requires a minimum intervention period of 12 weeks, and gains plateau or reverse within 4 to 8 weeks of treatment cessation without ongoing lifestyle maintenance." [14]

Safety Profile and Adverse Effects

MOTS-c's safety record in humans is limited by the small number of subjects studied formally. The phase I component of NCT04487626 reported no serious adverse events at doses up to 10 mg twice weekly over 12 weeks. [6] Reported mild adverse effects included:

• Injection-site erythema (8% of participants), resolving within 24 to 48 hours.
• Mild fatigue in the first 1 to 2 weeks (6% of participants), possibly reflecting metabolic adaptation.
• Transient hypoglycemia symptoms in 2 participants with pre-existing Type 2 diabetes on metformin; both resolved without intervention.

No hepatotoxicity, nephrotoxicity, or oncogenic signals were observed, though the sample size is far too small to rule out rare events. Long-term safety data simply do not exist yet.

Practitioners should counsel patients that MOTS-c is not FDA-approved for any indication. Compounded formulations are subject to variability in purity and concentration. Sourcing from a 503B outsourcing facility registered with FDA offers a higher manufacturing standard than a 503A compounding pharmacy for clinic-administered injections. [15]

Special Populations: Frailty and Fall Risk

Frailty and sarcopenia frequently overlap. Among community-dwelling adults over 75, the prevalence of both conditions simultaneously may reach 15 to 25%. [9] Fall-related injuries cost the U.S. Healthcare system an estimated $50 billion annually per CDC data. [1]

Adjusting the Protocol for Frail Patients

Frail older adults, defined by Fried criteria or a Clinical Frailty Scale score of 5 or higher, may not tolerate immediate dose escalation to 10 mg twice weekly. Consider:

• Extending Phase 1 (5 mg twice weekly) through week 8 before escalating.
• Prioritizing gait speed and chair-stand performance over DEXA lean mass as primary outcome markers, since functional gains matter more than compositional changes for fall prevention.
• Involving a physical therapist to supervise resistance training rather than leaving it to self-direction.

Interaction with Testosterone Replacement Therapy

Many older men on testosterone replacement therapy (TRT) for hypogonadism are also candidates for MOTS-c. No pharmacokinetic interaction data exist. Mechanistically, testosterone and MOTS-c act through different pathways (androgen receptor signaling versus AMPK), suggesting additive rather than redundant effects on muscle. Practitioners combining both therapies should monitor IGF-1 and hematocrit quarterly.

Comparing MOTS-c to Other Peptides Used in Sarcopenia

Clinicians often ask how MOTS-c stacks up against other peptides used off-label for muscle preservation.

BPC-157: Primarily used for connective tissue repair; limited direct evidence for lean mass accretion. [7]

CJC-1295 / Ipamorelin: Growth-hormone-releasing peptides that increase IGF-1. They drive muscle protein synthesis through a different upstream pathway. Some practitioners combine low-dose CJC-1295/Ipamorelin (100 mcg / 100 mcg nightly subcutaneous) with MOTS-c, though no trial data exist for the combination.

Follistatin-344: Inhibits myostatin. Animal data are compelling, but human safety data are essentially absent.

MOTS-c is currently the best-supported mitochondria-targeted option for sarcopenia, albeit from a low evidence base. Its glycemic benefits may offer secondary cardiovascular risk reduction in metabolically compromised older adults, an effect not shared by GH-axis peptides.

Regulatory and Sourcing Considerations

MOTS-c is not FDA-approved. It is legal to prescribe compounded MOTS-c under a physician's order through a licensed 503A or 503B compounding pharmacy in the United States, provided it is not a copy of a commercially available FDA-approved drug (which it is not, as of mid-2025). [15]

Clinicians should verify:

• The pharmacy holds a current state licensure and ideally PCAB accreditation.
• A certificate of analysis (CoA) from an independent third-party lab confirms purity (minimum 98% by HPLC) and absence of endotoxins (<5 EU/mL).
• The formulation specifies lyophilized powder with bacteriostatic water diluent, not pre-mixed solutions, for stability.

The FDA's guidance on compounding from bulk drug substances is relevant here; MOTS-c is not on the FDA's 503B bulks list as of this writing, meaning 503B facilities must operate under individual state board guidance. [15]